Shots: The two P-III studies involve assessing of VX-445 + tezacaftor + ivacaftor vs triple PBO & PBO + tezacaftor + ivacaftor in 405 & 108 patients with one F508del […]readmore
Tags : Vertex
Shots: Merck KGaA to receive upfront, milestones, and royalties on net sales. Vertex to get exclusive license rights for Merck’s two DNA-dependent protein kinase (DNA-PK) inhibitors, M9831 (formerly known as […]readmore
Shots: The approval is based on the results of ongoing P-III ARRIVAL study assessing Kalydeco in patients who have either of 10 mutations in the CFTR gene (G551D, G178R, S549N, […]readmore
Shots: The approval is based on the results of two P-III studies EVOLVE & EXPAND assessing Symkevi + Kalydeco vs PBO in 750 patients with CF having two copies of […]readmore
Shots: This collaboration plans to use human genetics and machine learning to address unmet needs by developing precision medicines Vertex will make £25M series B funding in Genomics (£10.5M equity […]readmore